This editorial refers to 'The non-canonical NOTCH ligand DLK1 exhibits a novel vascular role as a strong inhibitor of angiogenesis' by P. Rodríguez et al., pp. 232 -241, this issue.
The Notch signalling pathway is pivotal in normal vascular development and post-natal angiogenesis. Cumulative evidence supports the involvement of three canonical Notch ligands-Delta-like 1 (Dll1), Delta-like 4 (Dll4), and Jagged-1 (Jag1)-in the angiogenesis process. They are believed to function as Notch signalling agonists/antagonists to regulate the position and behaviour of endothelial cells under activated conditions. For instance, tissue-derived vascular endothelial growth factor (VEGF) induces the expression of the Dll4 ligand on endothelial tip cells, which in turn activates Notch signalling in neighbouring endothelial 'stalk' cells and restricts the emergence of excessive sprouting through repression of VEGF receptors and consequent reduction in responsiveness to VEGF. 1 -4 Moreover, Jag1
reportedly acts as an antagonist of the Dll4/Notch signalling in stalk cells, helping them maintain their activated phenotype. 5 In this context, the coordination of different components of the Notch signalling seems to be a key determinant for proper and functional neovascularization. 6, 7 Additionally, 'non-canonical' Notch ligands have been recently identified. These molecules are able to modify the Notch signalling response, thereby introducing an unexpected level of redundancy in the system. This redundancy might account for some pleiotropic features of Notch signalling. 8 The current findings from Rodríguez et al. show for the first time that the non-canonical Notch ligand Delta-like homologue 1 (DLK1) plays an inhibitory role on sprouting angiogenesis. DLK1, also known as pre-adipocyte factor 1 (Pref1), encodes a transmembrane glycoprotein that possesses epidermal growth factor-like motifs in the extracellular domain, similar to those present in the Delta/Notch/serrate family of signalling molecules. The inhibition of adipogenesis by DLK1 has been well established both in vitro and in vivo. DLK1 maintains precursor cell populations and inhibits differentiation. 10, 11 In their study, Rodríguez et al. have detected the expression of DLK1 protein in adult endothelial cells of different species. The DLK1 expression in endothelium was previously documented in mouse embryo and interestingly found to be highly expressed in branching sites. 12 However, the spatial and temporal expression of DLK1 during in vivo post-natal angiogenesis remains unknown (Figure 1) .
Using a loss-of-function/gain-of-function approach in wellestablished angiogenesis assays, the authors showed that DLK1 expression is inversely related to the formation of angiogenic endothelial networks. The inhibitory effect of DLK1 on angiogenesis is seemingly due to reduction in endothelial cell proliferation and migration rather than to an increase in apoptosis. A loss-of-function mouse model was also used to evaluate the contribution of DLK1 to retina angiogenesis. In this model, retinas were shown to contain high vascular density areas and more tip cells. The authors further investigated the role of DLK1 on angiogenesis in the zebrafish. DLK1 knockdown causes ectopic subintestinal vascularization. Conversely, DLK1 overexpression leads to aberrant vessel branching. The vascular defects resulting from DLK1 deficiency are similar to those observed in Dll4/Notchdeficient animals, although the phenotype is less severe in the former. The chosen genetic approach is certainly elegant, but not necessarily sufficient to dissect the complexity of the system and relative contribution of different partners. Hence, it would be important to further investigate the potential interaction between DLK1 and the canonical Notch ligands in these models.
Exploring the link between DLK1 and Notch signalling in DLK1
2/2 endothelial cells, Rodríguez et al. propose that the inhibitory effect of DLK1 on angiogenesis is mediated by the interaction with Notch receptors. Nevertheless, the mechanism of this interaction is still unclear in this context. Indeed, at variance with other Notch ligands, DLK1 does not have the DSL (Delta/Serrate/LAG2) domain which is believed to mediate the interaction and activation of Notch. Previous reports showed that DLK1 can interact with Notch through specific EGF-like repeats, thereby inhibiting the expression of Notch target genes such as Hes1 and acting as a Notch receptor antagonist. 13 A key question arising naturally here is how DLK1 might be involved in the cross-talk between the VEGF and Notch signalling pathways and how this interference could influence the sprouting and tip/stalk cell distribution. Further studies need to be performed to address the importance of DLK1 in pathological situations such as tumour angiogenesis or ischaemic diseases. These pathologies are characterized by activation of local cells as well as recruitment of inflammatory cells, which use provisional angiogenic networks as a structural platform to stimulate tissue growth and repair. We have recently shown that such an interaction is under control of the canonical Notch signalling pathway. 6 However, it remains unknown
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whether non-canonical ligands contribute to abnormal or reparative angiogenesis. Answering this question is of paramount importance for the development of new mechanistic therapeutic agents in human disease.
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